ORGN

Origin is a pre-commercial materials story dressed as a public equity, and the filing removes any ambiguity: management states there is "substantial doubt about our ability to continue as a going concern" and estimates existing cash carries planned operations only "into the third quarter of 2026." With a $5.15M market cap, $32.9M cash (down 41.5% YoY), and -$32.8M operating cash flow, the runway math is brutal — the company needs "a large amount of financing" it openly admits it struggles to raise because its "market capitalization and stock price severely constrain access to equity capital." The one lifeline, a $100M convertible facility, is described as effectively unusable at current prices without punishing dilution. This is a binary bankruptcy-or-massive-dilution setup, which the rubric treats as unknowable risk.

The fundamentals are not those of a growing company. FY2025 revenue fell 39.5% to $18.9M, and the modest sales come largely from a low-margin "supply chain activation program" reselling purchased materials — not the PET-closure product itself, which is still pre-revenue. Net income was -$250M (operating income -$259M), driven substantially by the February 2026 indefinite suspension of the entire furanics business and impairment of long-lived assets — the company wrote off a whole technology platform. Total assets collapsed 58.3% to $158M and retained deficit ballooned to -$288M. The -239.6% ROE and -1,369% operating margin are the arithmetic of a company spending vastly more than it earns.